Cytoki Pharma ApS — Credit Rating and Financial Key Figures
CVR number: 40594132
Vandtårnsvej 77, 2860 Søborg
rj@cytokipharma.com
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -6 039.75 | -31 975.16 | -98 763.65 | -61 547.81 | -39 132.58 |
| Employee benefit expenses | -1 448.39 | -4 987.06 | -8 079.39 | -8 546.22 | -7 177.85 |
| EBIT | -7 488.14 | -36 962.22 | - 106 843.04 | -70 094.02 | -46 310.42 |
| Other financial income | 5.30 | 1 705.52 | 4 475.34 | 587.51 | 1 697.99 |
| Other financial expenses | - 796.67 | - 292.26 | -1 525.89 | - 512.95 | - 149.27 |
| Pre-tax profit | -8 279.50 | -35 548.96 | - 103 893.59 | -70 019.47 | -44 761.70 |
| Income taxes | 1 486.07 | 5 795.70 | 5 500.00 | 5 500.00 | 5 500.00 |
| Net earnings | -6 793.43 | -29 753.26 | -98 393.59 | -64 519.47 | -39 261.70 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Other receivables | 18.41 | 99.98 | 81.21 | 139.98 | 146.98 |
| Investments total | 18.41 | 99.98 | 81.21 | 139.98 | 146.98 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current owed by particip. interest comp. | 1 781.77 | ||||
| Prepayments and accrued income | 16.00 | 116.55 | 193.92 | 182.78 | 236.53 |
| Current other receivables | 811.71 | 34 598.21 | 6 475.28 | 2 462.43 | 1 364.71 |
| Current deferred tax assets | 1 486.07 | 5 500.00 | 7 194.51 | 5 500.00 | 5 500.00 |
| Short term receivables total | 2 313.78 | 41 996.53 | 13 863.71 | 8 145.21 | 7 101.24 |
| Cash and bank deposits | 4 715.74 | 74 117.51 | 54 920.33 | 65 641.42 | 55 637.83 |
| Cash and cash equivalents | 4 715.74 | 74 117.51 | 54 920.33 | 65 641.42 | 55 637.83 |
| Balance sheet total (assets) | 7 047.93 | 116 214.03 | 68 865.25 | 73 926.61 | 62 886.05 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 199.78 | 244.01 | 326.56 | 357.29 |
| Retained earnings | -3 054.08 | 136 359.52 | 149 366.59 | 130 889.99 | 96 177.96 |
| Profit of the financial year | -6 793.43 | -29 753.26 | -98 393.59 | -64 519.47 | -39 261.70 |
| Shareholders equity total | -9 807.51 | 106 806.04 | 51 217.01 | 66 697.07 | 57 273.56 |
| Non-current liabilities total | |||||
| Current loans from credit institutions | 15 842.24 | ||||
| Current trade creditors | 786.60 | 8 235.42 | 17 309.17 | 6 690.44 | 4 638.32 |
| Current owed to participating | 1.35 | 1.77 | 1.77 | ||
| Other non-interest bearing current liabilities | 226.60 | 1 172.57 | 337.72 | 537.33 | 972.41 |
| Current liabilities total | 16 855.44 | 9 407.99 | 17 648.24 | 7 229.54 | 5 612.49 |
| Balance sheet total (liabilities) | 7 047.93 | 116 214.03 | 68 865.25 | 73 926.61 | 62 886.05 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.